Genes, Vol. 12, Pages 1599: Multiplex Protein Biomarker Profiling in Patients with Familial Hypercholesterolemia
Genes, Vol. 12, Pages 1599: Multiplex Protein Biomarker Profiling in Patients with Familial Hypercholesterolemia
Genes doi: 10.3390/genes12101599
Authors:
Dana Dlouha
Milan Blaha
Eva Rohlova
Jaroslav A. Hubacek
Vera Lanska
Jakub Visek
Vladimir Blaha
Familial hypercholesterolemia (FH), is an autosomal dominant disorder caused by mutations in the LDLR, APOB, PCSK9, and APOE genes and is characterized by high plasma levels of total and low-density lipoprotein (LDL) cholesterol. Our study aimed to analyze the influences of two different therapies on a wide spectrum of plasma protein biomarkers of cardiovascular diseases. Plasma from FH patients under hypolipidemic therapy (N = 18; men = 8, age 55.4 ± 13.1 years) and patients under combined long-term LDL apheresis/hypolipidemic therapy (N = 14; men = 7; age 58.0 ± 13.6 years) were analyzed in our study. We measured a profile of 184 cardiovascular disease (CVD) associated proteins using a proximity extension assay (PEA). Hypolipidemic therapy significantly (all p < 0.01) influenced 10 plasma proteins (TM, DKK1, CCL3, CD4, PDGF subunit B, AGRP, IL18, THPO, and LOX1 decreased; ST2 increased). Under combined apheresis/hypolipidemic treatment, 18 plasma proteins (LDLR, PCSK9, MMP-3, GDF2, CTRC, SORT1, VEGFD, IL27, CCL24, and KIM1 decreased; OPN, COL1A1, KLK6, IL4RA, PLC, TNFR1, GLO1, and PTX3 increased) were significantly affected (all p < 0.006). Hypolipidemic treatment mainly affected bioma...
Source: Genes - Category: Genetics & Stem Cells Authors: Dana Dlouha Milan Blaha Eva Rohlova Jaroslav A. Hubacek Vera Lanska Jakub Visek Vladimir Blaha Tags: Article Source Type: research